These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 37402062)

  • 1. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.
    Gordan JD; Keenan BP; Lim HC; Yarchoan M; Kelley RK
    Drugs; 2023 Aug; 83(12):1091-1109. PubMed ID: 37402062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Sho T; Suda G; Ohara M; Kohya R; Sasaki T; Yoshida S; Hosoda S; Ogawa K; Kitagataya T; Maehara O; Ohnishi S; Kawagishi N; Natsuizaka M; Nakai M; Baba M; Yamamoto Y; Tsukuda Y; Meguro T; Yamada R; Kobayashi T; Takagi T; Sakamoto N;
    Target Oncol; 2024 Sep; 19(5):769-778. PubMed ID: 39222223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
    Boilève J; Guimas V; David A; Bailly C; Touchefeu Y
    Curr Oncol; 2024 May; 31(6):3199-3211. PubMed ID: 38920726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
    Li SQ; Yang Y; Ye LS
    World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
    Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
    Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TKIs in combination with immunotherapy for hepatocellular carcinoma.
    Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
    Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
    Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.